Eduardo Angles-Cano

List of Publications by Year
in descending order

123 papers	5,989 citations	117625 34 h-index	74163 75 g-index
128 all docs	128 docs citations	128 times ranked	9826 citing authors

#	Article	IF	Citations
1	Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Annals of Intensive Care, 2021, 11, 14.	4.6	35
2	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©rosclÃ©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	1.6	9
3	Neutrophil Extracellular Traps Associate with Clinical Stages in Breast Cancer. Pathology and Oncology Research, 2020, 26, 1781-1785.	1.9	21
4	High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine, 2020, 46, 1089-1098.	8.2	2,244
5	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). Journal of Clinical Lipidology, 2020, 14, 487-497.e1.	1.5	17
6	Porphyromonas gingivalis triggers the shedding of inflammatory endothelial microvesicles that act as autocrine effectors of endothelial dysfunction. Scientific Reports, 2020, 10, 1778.	3.3	19
7	Prothrombotic phenotype in COVID-19 severe patients. Intensive Care Medicine, 2020, 46, 1502-1503.	8.2	39
8	Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer. Tohoku Journal of Experimental Medicine, 2020, 250, 121-128.	1.2	2
9	DNAâ€bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. FASEB Journal, 2019, 33, 14270-14280.	0.5	52
10	Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes. Lipids in Health and Disease, 2019, 18, 166.	3.0	8
11	Fibrin Î³/Î³' influences the secretion of fibrinolytic components and clot structure. BMC Molecular and Cell Biology, 2019, 20, 47.	2.0	5
12	New Copper Compounds with Antiplatelet Aggregation Activity. Medicinal Chemistry, 2019, 15, 850-862.	1.5	1
13	Endothelial Microparticles are Associated to Pathogenesis of Idiopathic Pulmonary Fibrosis. Stem Cell Reviews and Reports, 2018, 14, 223-235.	5.6	31
14	Evidence of Netosis in Septic Shock-Induced Disseminated Intravascular Coagulation. Shock, 2017, 47, 313-317.	2.1	81
15	Exome Sequencing and Clot Lysis Experiments Demonstrate the R458C Mutation of the Alpha Chain of Fibrinogen to be Associated with Impaired Fibrinolysis in a Family with Thrombophilia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 431-440.	2.0	6
16	Endothelial fibrinolytic response onto an evolving matrix of fibrin. BMC Hematology, 2016, 16, 9.	2.6	4
17	Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. Oncotarget, 2016, 7, 62255-62266.	1.8	20
18	Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Human Molecular Genetics, 2015, 24, 2390-2400.	2.9	47

#	Article	IF	Citations
19	Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling. , 2015, , .		0
20	Plasminogen in cerebrospinal fluid originates from circulating blood. Journal of Neuroinflammation, 2014, 11, 154.	7.2	4
21	Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator AÂchain. Journal of Thrombosis and Haemostasis, 2013, 11, 539-546.	3.8	22
22	Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers. Haematologica, 2013, 98, e75-e76.	3.5	3
23	Fibrinolytic microvesicles. Sang Thrombose Vaisseaux, 2013, 25, 100-110.	0.1	0
24	Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death and Differentiation, 2012, 19, 1983-1991.	11.2	60
25	Synergistic Effect of Thrombin and CD40 Ligand on Endothelial Matrix Metalloproteinase-10 Expression and Microparticle Generation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1477-1487.	2.4	53
26	Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis. Haematologica, 2012, 97, 1864-1872.	3.5	102
27	Lipoprotein(a) and Homocysteine Potentiate the Risk of Coronary Artery Disease in Male Subjects. Circulation Journal, 2012, 76, 1953-1957.	1.6	22
28	C0082 Circulating leukocyte- and endothelial-derived microparticles support a fibrinolytic activity. Thrombosis Research, 2012, 130, S115-S116.	1.7	0
29	Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking. Biophysical Journal, 2011, 100, 315a-316a.	0.5	0
30	Fibrinolysis, new concepts: fibrinolytic microvesicles and cross-talk. Hematologie, 2011, 17, 423-434.	0.0	0
31	Fluorescence single particle tracking for sizing of nanoparticles in undiluted biological fluids. , 2011, , .		0
32	Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitorâ€“Mediated Mechanism. Circulation, 2011, 124, 2909-2919.	1.6	54
33	Plasmin on adherent cells: from microvesiculation to apoptosis. Biochemical Journal, 2010, 432, 365-373.	3.7	31
34	Apo(a) phenotyping and long-term prognosis for coronary artery disease. Clinical Biochemistry, 2010, 43, 640-644.	1.9	7
35	Plasmin induces apoptosis of aortic valvular myofibroblasts. Journal of Pathology, 2010, 221, 37-48.	4.5	28
36	Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking. Nano Letters, 2010, 10, 4435-4442.	9.1	144

#	Article	IF	Citations
37	Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood, 2010, 115, 2048-2056.	1.4	77
38	Cellâ€derived microparticles: a new challenge in neuroscience. Journal of Neurochemistry, 2009, 110, 457-468.	3.9	89
39	Role of plasminogen activation in neuronal organization and survival. Molecular and Cellular Neurosciences, 2009, 42, 288-295.	2.2	21
40	Relationship between apo(a) length polymorphism and lipoprotein(a) concentration in healthy Ivorian subjects with single or double apo(a) isoforms. Clinical Biochemistry, 2008, 41, 1039-1043.	1.9	1
41	Mouse Model of In Situ Thromboembolic Stroke and Reperfusion. Stroke, 2007, 38, 2771-2778.	2.0	176
42	A case of afibrinogenemia associated with A-alpha chain gene compound heterozygosity (HUMFIBRA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	9
43	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thrombosis and Haemostasis, 2007, 98, 420-426.	3.4	33
44	Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood, 2007, 110, 2432-2439.	1.4	181
45	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thrombosis and Haemostasis, 2007, 98, 420-6.	3.4	16
46	Interaction of Fibrin(ogen) with Apolipoprotein(a):â€‰ Further Characterization and Identification of a Novel Lysine-Dependent Apolipoprotein(a)-Binding Site within the Î³ Chain 287â€“411 Region. Biochemistry, 2006, 45, 10624-10632.	2.5	9
47	Plasminogen activator inhibitor-1 impairs plasminogen activationmediated vascular smooth muscle cell apoptosis. Thrombosis and Haemostasis, 2006, 96, 665-670.	3.4	21
48	Functional characterization of fibrinogen BicÃªtre II: a Î³ 308 Asnâ†'Lys mutation located near the fibrin D:D interaction sites. Blood Coagulation and Fibrinolysis, 2006, 17, 193-201.	1.0	7
49	Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. Journal of Thrombosis and Haemostasis, 2006, 4, 664-670.	3.8	45
50	Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Bloodâ€“Cerebrospinal Fluid Barrier Dysfunction. Clinical Chemistry, 2006, 52, 2043-2048.	3.2	11
51	Ethnicity and lipoprotein(a) polymorphism in Native Mexican populations. Annals of Human Biology, 2006, 33, 202-212.	1.0	6
52	Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells. Thrombosis and Haemostasis, 2006, 95, 142-150.	3.4	4
53	Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. FEBS Journal, 2005, 272, 3387-3400.	4.7	27
54	Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma. Thrombosis and Haemostasis, 2005, 94, 75-81.	3.4	9

#	Article	IF	Citations
55	The plasminogen?MMP system is more activated in the scar than in viable myocardium 3ï¿½months post-MI in the rat. Journal of Molecular and Cellular Cardiology, 2005, 38, 193-204.	1.9	27
56	Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a). Thrombosis and Haemostasis, 2004, 92, 1066-1075.	3.4	12
57	Protease Nexin-1 Inhibits Plasminogen Activation-induced Apoptosis of Adherent Cells. Journal of Biological Chemistry, 2004, 279, 10346-10356.	3.4	90
58	How statins and fibrates lower CRP. Blood, 2004, 103, 3996-3997.	1.4	3
59	VASCULAR SMOOTH MUSCLE CELL APOPTOSIS IN ATHEROSCLEROTIC PLAQUES IS MEDIATED BY PLASMINOGEN ACTIVATION. Journal of Hypertension, 2004, 22, S13.	0.5	0
60	Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. European Journal of Clinical Investigation, 2003, 33, 99-105.	3.4	8
61	Pericellular plasmin induces smooth muscle cell anoikis. FASEB Journal, 2003, 17, 1301-1303.	0.5	97
62	Identification and Characterization of Novel Lysine-independent Apolipoprotein(a)-binding Sites in Fibrin(ogen) Î±C-domains. Journal of Biological Chemistry, 2003, 278, 37154-37159.	3.4	24
63	Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1232-1238.	2.4	47
64	Apolipoprotein(a): Structure-Function Relationship at the Lysine-Binding Site and Plasminogen Activator Cleavage Site. Biological Chemistry, 2002, 383, 93-9.	2.5	20
65	Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension. Blood Coagulation and Fibrinolysis, 2002, 13, 417-422.	1.0	9
66	Involvement of the Mural Thrombus as a Site of Protease Release and Activation in Human Aortic Aneurysms. American Journal of Pathology, 2002, 161, 1701-1710.	3.8	285
67	Hemostasis Imbalance in Experimental Hypertension. Molecular Medicine, 2002, 8, 169-178.	4.4	17
68	Bivalency of plasminogen monoclonal antibodies is required for plasminogen bridging to fibrin and enhanced plasmin formation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2002, 1598, 165-176.	2.3	5
69	ANTIPHOSPHOLIPID ANTIBODIES AND THE COAGULATION CASCADE. Rheumatic Disease Clinics of North America, 2001, 27, 573-586.	1.9	12
70	Binding of Recombinant Apolipoprotein(a) to Human Platelets and Effect on Platelet Aggregation. Thrombosis and Haemostasis, 2001, 85, 686-693.	3.4	44
71	Experimental Study of Fibrin/Fibrin-Specific Molecular Interactions Using a Sphere/Plane Adhesion Model. Journal of Colloid and Interface Science, 2001, 241, 52-62.	9.4	35
72	Elevated plasma tissue plasminogen activator and anti-THP-1 antibodies are independently associated with decreased graft survival in cardiac transplant recipients. American Journal of Cardiology, 2001, 88, 30-34.	1.6	5

#	Article	IF	Citations
73	Kringles of the plasminogenâ€“prothrombin gene family share conformational epitopes with recombinant apolipoprotein (a): specificity of the fibrin-binding site. BBA - Proteins and Proteomics, 2001, 1548, 72-80.	2.1	13
74	Inhibition of Fibrinolysis by Lipoprotein(a). Annals of the New York Academy of Sciences, 2001, 936, 261-275.	3.8	94
75	Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. British Journal of Haematology, 2000, 108, 871-875.	2.5	35
76	Lipoprotein Lp(a) and Atherothrombotic Disease. Archives of Medical Research, 2000, 31, 353-359.	3.3	45
77	High Antifibrinolytic Activity of Lipoprotein(a) Containing Small Apolipoprotein(a) Isoforms. Circulation, 2000, 102, E184-5.	1.6	1
78	Experimental Study of Fibrin Embolization Under Shear Flow. Journal of Adhesion, 2000, 72, 229-239.	3.0	7
79	Effect of Individual Plasma Lipoprotein(a) Variations In Vivo on Its Competition With Plasminogen for Fibrin and Cell Binding. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 575-584.	2.4	29
80	Evidence that Modifications of Lp(a) In Vivo Inhibit Plasmin Formation on Fibrin. Thrombosis and Haemostasis, 1999, 82, 121-127.	3.4	20
81	Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site. BBA - Proteins and Proteomics, 1999, 1434, 124-134.	2.1	7
82	Immobilisation of Monocytes to a Solid Support. Thrombosis Research, 1999, 96, 473-480.	1.7	3
83	Advances in autoantibodies in SLE. Lupus, 1998, 7, 507-514.	1.6	14
84	Fibrino(geno)lytic Properties of Purified Hementerin, a Metalloproteinase from the Leech Haementeria depressa. Thrombosis and Haemostasis, 1998, 80, 155-160.	3.4	26
85	Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 274-278.	5.6	56
86	2.P.99 A novel kringle-4 number-based recombinant apo(a) standard for human Lp(a) phenotyping. Atherosclerosis, 1997, 134, 137.	0.8	0
87	2.P.120 Identification of kringles of apolipoprotein(a) that enable its binding to fibrin and monocytic cells. Atherosclerosis, 1997, 134, 141.	0.8	0
88	2.P.121 Binding of apo(a) isoforms to fibrin is modified by their incorporation into an LDL lipoparticle. Atherosclerosis, 1997, 134, 142.	0.8	2
89	2.P.132 A fibrin-binding method for the functional identification of lipoprotein(a) in plasma from patients with cardiovascular disease. Atherosclerosis, 1997, 134, 144.	0.8	0
90	Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Brazilian Journal of Medical and Biological Research, 1997, 30, 1271-1280.	1.5	19

#	Article	IF	Citations
91	Lipoprotein(a) Isoforms Display Differences in Affinity for Plasminogen-Like Binding to Human Mononuclear Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2036-2043.	2.4	34
92	Development and clinical application of a new ELISA assay to determine plasminâ€“Î±₂â€antiplasmin complexes in plasma. British Journal of Haematology, 1996, 92, 979-985.	2.5	48
93	The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. European Journal of Clinical Investigation, 1996, 26, 411-417.	3.4	37
94	Review : Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Lupus, 1996, 5, 275-278.	1.6	26
95	Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. American Journal of Hematology, 1995, 49, 109-114.	4.1	14
96	Multiple Binding with Identical Linkage: A Mechanism That Explains the Effect of Lipoprotein(a) on Fibrinolysis. Biochemistry, 1995, 34, 13353-13358.	2.5	48
97	Limited Proteolysis of Human Î±-Thrombin by Urokinase Yields a Non-Clotting Enzyme. Thrombosis and Haemostasis, 1995, 73, 275-280.	3.4	4
98	Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension. Thrombosis and Haemostasis, 1995, 73, 735-736.	3.4	32
99	Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surfaces. Chemistry and Physics of Lipids, 1994, 67-68, 353-362.	3.2	74
100	Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. Chemistry and Physics of Lipids, 1994, 67-68, 369-380.	3.2	35
101	Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen. FEBS Journal, 1994, 219, 961-967.	0.2	31
102	Endothelial Cell Markers (vWF, t-PA and PAI-1) in the Elderly. Thrombosis and Haemostasis, 1994, 72, 164-165.	3.4	3
103	Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. FEBS Journal, 1993, 216, 549-556.	0.2	44
104	A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators. Fibrinolysis, 1993, 7, 87-96.	0.5	22
105	Neutralization of plasminogen activator inhibitor-1 (PAI-1) by activated protein C is species-dependent. Fibrinolysis, 1993, 7, 123-133.	0.5	3
106	Relevance of lipoprotein (a) in cardiovascular disease: Methodological approaches. Fibrinolysis, 1993, 7, 66-68.	0.5	5
107	The mutation in fibrinogen BicÃªtre II (Î³ Asn308 â†’Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coagulation and Fibrinolysis, 1993, 4, 679-687.	1.0	4
108	Plasminogen binding by Î±2-antiplasmin and histidine-rich glycoprotein does not inhibit plasmiogen activation at the surface of fibrin. Biochimica Et Biophysica Acta - General Subjects, 1992, 1156, 34-42.	2.4	22

#	Article	IF	Citations
109	Plasma levels of single-chain urokinase in the elderly. Fibrinolysis, 1992, 6, 66-67.	0.5	3
110	Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry, 1992, 31, 6333-6339.	2.5	95
111	The activation of plasminogen by tissue plasminogen activator is not enhanced by different heparin species as assessed in vitro with a solid-phase fibrin method. Fibrinolysis, 1991, 5, 61-69.	0.5	4
112	Characterization of the binding of plasminogen to fibrin surfaces: The role of carboxy-terminal lysines. Biochemistry, 1991, 30, 7630-7638.	2.5	186
113	The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1. BBA - Proteins and Proteomics, 1991, 1079, 321-329.	2.1	7
114	Development of an internal standard for plasminogen activator inhibitor-1 PAI-1 and its use in a simplified assay for measuring pai-1 activity in human plasma. Fibrinolysis, 1990, 4, 127-129.	0.5	2
115	Relationship Between Plasminogen Activators and Regeneration Capacities of Rat Skeletal Muscles. , 1990, , 229-241.		3
116	The pH Dependence of the Binding of Pro-Urokinase to Fibrin/Celite. Thrombosis and Haemostasis, 1990, 64, 556-558.	3.4	3
117	A method for the determination of the affinity constant of antibodies to tissue plasminogen activator. Thrombosis Research, 1988, 50, 687-694.	1.7	0
118	Solid-phase fibrin-tissue-plasminogen-activator activity assay (sofia-TPA): TPA but not uk is specifically detected. Thrombosis Research, 1986, 43, 129-132.	1.7	4
119	Polyunsaturated fatty acids increase fibrinolytic activity of human isolated glomeruli. Kidney International, 1986, 30, 701-705.	5.2	13
120	A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activator. Analytical Biochemistry, 1986, 153, 201-210.	2.4	89
121	Heterogeneity of plasminogen activator expression in various moloney virus-induced tumor cell lines. Lack of correlation with tumor growth and cell phenotype. International Journal of Cancer, 1984, 33, 277-280.	5.1	19
122	A solid-phase fibrin immunoassay for the specific detection of monoclonal antibodies against different epitopic determinants of tissue-plasminogen activators. Journal of Immunological Methods, 1984, 69, 115-127.	1.4	15
123	Release of VIII R:Ag and VIII R:WF during thrombin and collagen induced aggregation. Thrombosis Research, 1979, 15, 415-425.	1.7	14